For instance, GLP-1 receptor agonists can reduce body weight, improve IR, lower liver enzyme levels, and reduce liver fat content in patients with T2DM, which may be beneficial for the treatment of NAFLD/NASH (69). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.